| Description | Salicyl-AMS is an inhibitor of mycobacterium auxin biosynthesis that inhibits the growth of mycobacterium in the presence of iron deficiency in vitro. |
| In vitro | Salicyl-AMS是一种强效的抑制剂，用于抑制细菌铁载体生物合成中的水杨酸腺苷酰化酶，并且是治疗结核病的有希望的先导化合物。[1] |
| In vivo | Salicyl-AMS（一种结核分枝杆菌生物合成抑制剂）在铁限制条件下可抑制体外M. tuberculosis的生长。我们对Salicyl-AMS进行了单剂量药代动力学研究和小鼠单药疗法研究。结果显示，腹腔注射的药代动力学参数明显优于口服给药。Salicyl-AMS以5.6或16.7 mg/kg的剂量进行单药疗法，显著抑制了小鼠肺部M. tuberculosis的生长。[2] |
| molecular weight | 466.43 |
| Molecular formula | C17H18N6O8S |
| CAS | 863238-55-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 81.5 mg/mL (174.6 mM) |
| References | 1. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193-206. 2. Lun S, et al. Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice. Antimicrob Agents Chemother. 2013;57(10):5138-5140. 3. Ferreras JA, et al. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat Chem Biol. 2005;1(1):29-32. |